Format

Send to

Choose Destination
See comment in PubMed Commons below
Radiother Oncol. 2010 Aug;96(2):199-203. doi: 10.1016/j.radonc.2010.02.028. Epub 2010 Mar 27.

Breast radiotherapy as part of loco-regional treatments in stage IV breast cancer patients with oligometastatic disease.

Author information

1
Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France. bourgier@igr.fr

Abstract

BACKGROUND:

Local treatments seem to improve metastasis progression-free survival (MPFS) and overall survival (OS) when added to systemic therapies in stage IV breast cancer.

METHODS:

From 1990 to 2003, we reviewed 9138 cases treated and registered in the Institut Gustave-Roussy breast cancer database. Among them, 308 had presented with stage IV disease. Eighty percent of patients (n=239) had received a loco-regional treatment and they were categorized into two groups: loco-regional radiotherapy (LRRT) alone (Group 1; n=147) or breast and axillary surgery+/-LRRT (Group 2; n=92).

RESULTS:

The median follow-up was 6.5 years. LRRT obtained a long-standing loco-regional clinical response in 85% of patients. The 3-year MPFS rates were 20% in Group 1 and 39% in Group 2; the 3-year OS rates were 39% and 57%, respectively. However, no significant differences in MPFS or OS were observed between the two groups when adjusted on prognostic factors.

CONCLUSIONS:

Radiation therapy alone provides long-standing local control and yields MPFS and OS rates equivalent to those obtained when radiation therapy is combined with surgery, whatever the prognostic factors. Loco-regional therapies, especially radiation therapy alone, may have an important role to play in the treatment of selected patients with stage IV breast cancer.

PMID:
20347167
DOI:
10.1016/j.radonc.2010.02.028
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center